In 2023, weight loss drugs have taken the health care industry by storm, with Ro CEO Zachariah Reitano reporting increased demand for obesity treatments on his telehealth platform. The GLP-1 drugs, discovered in the 1980s and first approved in 2005 for type 2 diabetes, were honored as the Breakthrough of the Year by Science Magazine for their role in addressing obesity-related health issues. As these drugs gain traction, a team of researchers is preparing to recruit patients in 2024 for a study to explore how new obesity medications can be best incorporated into regular medical practice. Novo Nordisk, following the success of its drug Wegovy, is aiming to eradicate obesity with the development of long-lasting RNAi treatments and preventative strategies. Wegovy, which functions by mimicking fullness-inducing hormones, is being considered as an alternative to bariatric surgery and is being used in conjunction with it in some cases. The emergence of these drugs raises questions about their cost, societal value, and potential applications beyond obesity, such as in treating addictions.
They were intended to treat diabetes. The other benefits of a new generation of weight-loss drugs were discovered by accident https://t.co/YO2t1jLQBr 👇
Weight loss drugs took health care by storm in 2023 🩺 @ro CEO @ZReitano walks us through the increased demand he's seeing for obesity treatments and how his platform uses telehealth to oversee prescriptions for eligible patients. https://t.co/bjsaGA3jIP
serendipity in drug discovery: Viagra developed as a treatment for angina initially parallels to GLP-1 agonists, first developed for diabetes. Now used for obesity and potentially addictions + others in the future https://t.co/i4BifB7SOm
I first learned about Wegovy / Ozempic (same drug) because of the jokes. One of the biggest stories of the year. Unlike fad diet drugs like Hydroxycut, this is a real compound. In short, it mimics hormones in the body tell you you're full -- hence restricting appetite. The…
NEW: After introducing the world to Wegovy, Novo is now on a mission to eliminate obesity altogether. It's researching long-lasting RNAi treatments, "working towards a cure." It's also studying ways to prevent obesity. w/ @DrewQJoseph, @damiangarde https://t.co/XYhxNDtDIO
What comes after Wegovy? The quest to eradicate obesity https://t.co/aUaXvWxTAj
📆 1980’s: GLP-1 discovered while investigating blood sugar regulation 📆 2005: First GLP-1 drug approved for type 2 diabetes 📆 2023: GLP-1 drugs found to blunt obesity-associated health problems, earning @ScienceMagazine Breakthrough of the Year https://t.co/pjUbD0n6wQ
How the new vision for an obesity-free future raises difficult questions about cost, equity and societal value: "What comes after Wegovy?'' #ObesityRevolution @elaineywchen @DrewQJoseph @damiangarde https://t.co/o2OCbI3Q4O via @statnews
The companies that started an obesity revolution with drugs like Wegovy and Zepbound are jumping into the next phase: a mission to eliminate obesity altogether. https://t.co/ng0A9C3ecp
They’ve been growing in popularity: drugs to help people shed pounds. Now, as new research emerges, doctors are seeing multiple benefits. https://t.co/JZrCAw86AN
For years, doctors had one strategy for heart-attack prevention: statins. Suddenly, they have several weapons in their arsenal. https://t.co/xqdlf43Hu7 https://t.co/xqdlf43Hu7
In 2024, a team of researchers will begin recruiting patients for a study driven by a pressing question in medicine: How should new obesity medications be incorporated into regular practice? https://t.co/7YVkhwZ7ny
A new trial in Europe aims to figure out how new obesity drugs should be incorporated into regular practice. It'll look at the effectiveness of drugs vs lifestyle changes vs surgery + the cost-effectiveness of different approaches. via @DrewQJoseph https://t.co/Twct5ZTqIv
Latest #ObesityRevolution installment. @DrewQJoseph reports from London: New weight loss drugs have proven their effectiveness. Now researchers want to know how to best use them https://t.co/6HWgg8RuHc via @statnews
The new highly effective class of anti-obesity drugs has often been talked about as an alternative to bariatric surgery — but medications like Wegovy are increasingly being paired with the procedure. https://t.co/xxqLl1RkYV
A team of researchers will soon launch a study driven by a pressing question in medicine: How should new obesity medications be incorporated into regular practice? https://t.co/NroPNoHd4g
This pill is called “VIBES” and it helps you feel full. Used for inducing satiety prematurely for obese individuals, using vibrations it lets out in the stomach. https://t.co/lhdWfJz3WB